Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Net Income Loss of -$84.95 million for the year ending 2025.
- INOVIO PHARMACEUTICALS, INC. showed an increase of +20.8% in Net Income Loss from 2024 to 2025.
- This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$30.88 million | Q4 2013: -$15.45 million | Q1 2014: -$10.82 million | Q2 2014: -$10.71 million | Q3 2014: -$7.18 million | Q4 2014: -$7.41 million | Q1 2015: -$10.58 million | Q2 2015: -$6.25 million | Q3 2015: $5.59 million | Q4 2015: -$17.95 million | Q1 2016: -$8.04 million | Q2 2016: -$18.70 million | Q3 2016: -$20.76 million | Q4 2016: -$26.23 million | Q1 2017: -$23.09 million | Q2 2017: -$9.48 million | Q3 2017: -$34.13 million | Q4 2017: -$21.51 million | Q1 2018: -$32.35 million | Q2 2018: -$6.64 million | Q3 2018: -$25.02 million | Q1 2019: -$29.22 million | Q2 2019: -$29.39 million | Q3 2019: -$23.09 million | Q4 2019: -$37.66 million | Q1 2020: -$32.54 million | Q2 2020: -$128.70 million | Q3 2020: $19.17 million | Q4 2020: -$24.34 million | Q1 2021: -$54.40 million | Q2 2021: -$82.14 million | Q3 2021: -$60.17 million | Q1 2022: -$79.07 million | Q2 2022: -$108.50 million | Q3 2022: -$37.78 million | Q1 2023: -$40.65 million | Q2 2023: -$35.53 million | Q3 2023: -$33.93 million | Q1 2024: -$30.47 million | Q2 2024: -$32.24 million | Q3 2024: -$25.17 million | Q1 2025: -$19.69 million | Q2 2025: -$23.52 million | Q3 2025: -$45.50 million.
- Over the full 17 years of available data (2009 to 2025), INOVIO PHARMACEUTICALS, INC.'s Net Income Loss has declined by 248.0%.
- Historical annual values: Fiscal year 2025: -$84.95 million | Fiscal year 2024: -$107.25 million | Fiscal year 2023: -$135.12 million | Fiscal year 2022: -$279.82 million | Fiscal year 2021: -$303.66 million | Fiscal year 2020: -$166.41 million | Fiscal year 2019: -$119.36 million | Fiscal year 2018: -$96.97 million | Fiscal year 2017: -$88.21 million | Fiscal year 2016: -$73.74 million | Fiscal year 2015: -$29.19 million | Fiscal year 2014: -$36.12 million | Fiscal year 2013: -$66.03 million | Fiscal year 2012: -$19.67 million | Fiscal year 2011: -$15.25 million | Fiscal year 2010: -$17.61 million | Fiscal year 2009: -$24.41 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: